Thrombotic thrombocytopenic purpura (TTP) occurring in association with pregnancy was first reported in 1955 [1], 30 years after TTP was initially described in a young woman [2] . This case report [1] described a 19-year-old woman in the eighth month of her first pregnancy who was admitted with edema, headache, nausea, vomiting, and abdominal pain. She was mildly hypertensive and had albuminuria. On the fourth day after she spontaneously delivered a healthy premature infant, she had mental status changes and developed anemia and aphasia. On the ninth postpartum day she became comatose with right hemiplegia and developed thrombocytopenia and renal insufficiency. She died on her eleventh postpartum day. Autopsy demonstrated the characteristic disseminated microvascular thrombi of TTP in most organs.
The onset, progression, and outcome of TTP in this young woman are characteristic of the frequent subsequent reports of TTP associated with pregnancy: (1) gastrointestinal abnormalities are common presenting symptoms; (2) preeclampsia (hypertension) is often present; (3) the occurrence is most common at term with progression following delivery; (4) both severe neurologic abnormalities and renal failure occur; and (5) death from disseminated microvascular thrombosis occurs without plasma exchange treatment. This review will summarize the data supporting a causal association between pregnancy and the occurrence of TTP-HUS (thrombotic thrombocytopenic purpura-hemolytic uremic syndrome).
Current diagnostic criteria, thrombocytopenia and microangiopathic hemolytic anemia without another apparent etiology, do not distinguish TTP from HUS. Although it is commonly stated that patients with TTP have predominant neurologic abnormalities while patients with HUS have predominant renal insufficiency, in fact many patients have both severe neurologic and renal abnormalities, and other patients have neither neurologic nor renal abnormalities. Therefore among adults, the distinction of TTP from HUS is not clear. HUS is an appropriate diagnostic term for young children who have thrombocytopenia, microangiopathic hemolytic anemia, and acute renal failure caused by Shiga toxin-producing enterohemorrhagic strains of Escheria coli. These children almost always recover with only supportive care, without plasma exchange treatment. However, adult patients diagnosed with either syndrome are treated with plasma exchange because adults rarely survived in the era prior to plasma exchange [3]; plasma exchange has de-creased mortality to 20% in patients with or without renal failure [4, 5] .
In previous discussions of pregnancy and TTP or HUS, it has been suggested that TTP occurs earlier during pregnancy while HUS occurs near term or postpartum [6,7•]. However, the basis for these statements is unclear. Case series often do not distinguish patients with TTP from patients with HUS, and when a distinction is made, no quantitative or reproducible criteria are provided to support the distinction. Although pregnancy can precipitate an acute episode of TTP-HUS early in pregnancy, most acute episodes described as TTP or HUS occur near term or postpartum.
For these reasons, this review will not distinguish TTP from HUS, but rather will use the comprehensive term, TTP-HUS, to describe these syndromes.
Frequency of pregnancy in case series of patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome
The association of pregnancy with TTP-HUS is suggested by the common occurrence of pregnancy in reported case series. The reason for the predominance of women among patients with TTP-HUS is not known, but it may be related to the potential autoimmune pathogenesis of TTP-HUS and the predominance of women among patients with other autoimmune disorders. The frequency of Pregnancy as a precipitating event for women with familial or congenital thrombotic thrombocytopenic purpura-hemolytic uremic syndrome
Reports of women with congenital TTP-HUS who had their first episode during their first pregnancy more clearly support pregnancy as a precipitating event. Table  2 describes 14 women from eight families with congenital TTP-HUS, documented either by deficiency of ADAMTS13 activity without a demonstrable inhibitor or by familial occurrence, who had their initial presentation of TTP-HUS during their first pregnancy [11, [29] [30] [31] [32] [33] [34] [35] . The time of occurrence during pregnancy was documented in nine women; in six, TTP-HUS occurred at 30 to 38 weeks (Table 2) , consistent with the most common occurrence of TTP-HUS later during pregnancy in all case series (Table 1) .
Among all patients with a congenital deficiency of ADAMTS13, there appear to be two age clusters for the initial episode: about half of patients have their first acute episode in infancy or early childhood while the other half of patients remain asymptomatic until adulthood [11] . In families seven and eight (Table 2) , two sisters each had their first episode of TTP-HUS during their first pregnancy. In each of these two families, a brother also had absent ADAMTS13 activity without an inhibitor, but neither of these adult men have ever had signs or symptoms of TTP-HUS [11]. These observations suggest that in families seven and eight, pregnancy precipitated the initial acute episode of TTP-HUS. Each of these women has had subsequent episodes of TTP-HUS in the absence of pregnancy, suggesting that the occurrence of an initial episode may predispose to further episodes [11] .
An additional woman with congenital TTP-HUS, the index patient with Upshaw-Shulman syndrome who had repeated severe episodes with her first pregnancy, was described by Upshaw [12] . This patient is not included in Physiologic changes during pregnancy and pregnancyassociated complications that may contribute to risk for TTP-HUS include hypercoagulability with an increased risk for thrombosis, especially in women with genetic thrombophilia, and the progressive ADAMTS13 deficiency, which occurs during the course of pregnancy.
Hypercoagulability during pregnancy
Multiple changes of the hemostatic system progressively occur during the course of pregnancy, with the greatest abnormalities occurring at term. Fibrinogen, factor VIII, and von Willebrand factor increase 1.5-to 3.0-fold during the course of pregnancy, with peak values occurring immediately following delivery [15] . Increasing levels of factor VIIa by more than two-fold during the course of pregnancy are evidence for coagulation activation [16] . The decreasing platelet counts that occur during pregnancy may also reflect activated intravascular coagulation [17, 18] . Increasing plasma levels of thrombomodulin demonstrate loss of integral endothelial cell membrane proteins during the course of pregnancy [19] . Fibrinolytic activity progressively diminishes during the course of pregnancy, associated with increasing levels of plasminogen activator inhibitor-1 [19] . These changes, all features of disseminated intravascular coagulation, are greatest at the time of a placental separation and greatest in the uterine venous circulation [20] . 
Risk for thrombosis during pregnancy
The increased risk for thrombosis during pregnancy is primarily manifested by venous thromboembolic disease. Deep venous thrombosis of the legs may be related to the hypercoagulable state associated with pregnancy, but may also be related to venous stasis caused by inferior vena cava compression. A more important consideration related to TTP-HUS is the increased occurrence of stroke during pregnancy, which occurs primarily at the time of delivery or postpartum [21] . Although stroke is a rare complication of pregnancy, its frequency during pregnancy far exceeds the frequency in nonpregnant young women [21] .
Increased risk for thrombosis and complications of pregnancy in women with genetic thrombophilia
Women with genetic risk factors for thrombosis, including factor V Leiden, the C677T mutation of the methylenetetrahydrofolate reductase gene, the G20210A mutation of the prothrombin gene, as well as deficiencies in protein S, protein C, and anti-thrombin III, have a higher frequency of pregnancy-related complications, including severe preeclampsia [22] . In a case control study, 52% of otherwise healthy women who had severe complications of pregnancy had one of these genetic risk factors. In another case control study, factor V Leiden and prothrombin gene mutations were associated with a nearly three-fold risk of late fetal loss [23] . These observations suggest that genetic risk factors for thrombosis are associated with multiple complications of pregnancy and may also contribute to the increased risk for TTP-HUS [14•].
The occurrence of ADAMTS13 deficiency during pregnancy ADAMTS13 activity progressively decreases during the course of pregnancy [24] . In this study, the mean values of ADAMTS13 activity in women during the second and third trimesters (64%, range 22-135%) were significantly lower than during the first trimester (94%, range 40-160%) [24] . The mechanism for decreased ADAMTS13 activity during pregnancy may be related to the physiologic increase of von Willebrand factor concentration [15] , as ADAMTS13 activity has been shown to be inversely correlated with plasma von Willebrand factor concentrations [25] . The decreased ADAMTS13 activity levels documented during late pregnancy are not as low as the undetectable levels associated with acute episodes of TTP-HUS [26, 27] . In case series of patients with TTP-HUS, a severe deficiency with undetectable activity is considered to be a specific abnormality for TTP-HUS [28] . However, the moderate deficiency described in late pregnancy may be an additional risk for women who have other risk factors for thrombosis. For example, women who are heterozygous for ADAMTS13 deficiency may become more severely deficient during pregnancy. Also, women with additional risk factors for TTP-HUS factors for thrombosis, such as obesity and the factor V Leiden mutation, may be at additional risk for TTP-HUS in the presence of moderate ADAMTS13 deficiency.
ADAMTS13 deficiency in women with pregnancy-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome
In a report of 142 consecutive patients with clinically diagnosed TTP-HUS, severe ADAMTS13 deficiency (activity < 5%) occurred only in patients with idiopathic TTP-HUS or in whom the TTP-HUS was associated with pregnancy [9••]. Severe ADAMTS13 deficiency did not occur in patients whose acute episode of TTP-HUS was associated with bone marrow transplantation, drugs, a prodrome of bloody diarrhea, or additional disorders such as autoimmune diseases and HIV infection [9••]. The association of severe ADAMTS13 deficiency with idiopathic TTP-HUS is consistent with previous reports [26, 27] . The occurrence of severe ADAMTS13 deficiency in two of 10 patients with pregnancyassociated TTP-HUS further documents the importance of pregnancy as a precipitating factor. Neither of these women had hypertension or other signs of preeclampsia. In one of these women, the acute onset of signs and symptoms of TTP-HUS occurred immediately prior to delivery, and the diagnosis was made immediately after delivery. The other woman had an uncomplicated pregnancy and delivery and did not become acutely ill until 1 week postpartum [9••]. The peripartum and postpartum occurrences in these two women are consistent with other reports that acute episodes most commonly occur late during pregnancy or postpartum (Tables 1, 2) .
Conclusions
Pregnancy as a precipitating event for acute episodes of TTP-HUS is clear from many case series, including reports of women with congenital TTP-HUS. Pregnancy may be a risk factor for acute episodes of TTP-HUS because of the association of pregnancy with increasing concentrations of procoagulant factors, decreasing fibrinolytic activity, loss of endothelial cell thrombomodulin, and decreasing activity of ADAMTS13. All of these abnormalities become progressively more severe through the course of pregnancy, with the maximum abnormalities occurring at delivery and immediately postpartum.
Although pregnancy as a precipitating event for acute episodes of TTP-HUS seems clear, the risk of pregnancy is not predictable. Future clinical research must systematically evaluate the risk of subsequent pregnancies for women who have recovered from an acute episode of TTP-HUS. Also, the distinction of pregnancy-related syndromes, such as preeclampsia, eclampsia, and the HELLP syndrome, from TTP-HUS may not always be possible. Whether the etiologies of these syndromes, which share many clinical manifestations with TTP-HUS, are related to the etiologies of TTP-HUS is unknown. Future clinical research must correlate ADAMTS13 activity during pregnancy with the physiologic changes in hemostasis and the pathologic occurrence of pregnancy-related complications.
